Investigación traslacional en Cáncer y otras enfermedades crónicas prevalentes
Lineas de Investigación
01. Evaluación de Servicios de Salud en enfermedades oncológicas
02. Estudio de proteínas inhibidoras de apoptosis en cáncer
03. Estudio de Biomarcadores de Inmunoedición y de Respuesta a la Inmunoterapia en cáncer, y resultados en salud atribuibles a dicha inmunoterapia.
Miembros del grupo
- Todos
- IR
- Co-IR
- Investigador
- Tecnico Laboratorio
- Otro
Proyectos de Investigación
RD16/0001/0006 Red de Investigación en Servicios de Salud en Enfermedades Crónicas – REDISSEC
INSTITUTO DE SALUD CARLOS III
ACCIÓN ESTRATÉGICA EN SALUD - CONVOCATORIA DE REDES TEMÁTICAS DE INVESTIGACIÓN COOPERATIVA EN SALUD (RETICS)
2016
PI18-01181 Identificación de factores de riesgo de eventos adversos y Calidad de Vida en pacientes supervivientes de cáncer de colon y recto a 8 y 10 años de seguimiento post-cirugía.
INSTITUTO DE SALUD CARLOS III
ACCIÓN ESTRATÉGICA EN SALUD - PROYECTOS DE INVESTIGACIÓN EN SALUD
2018
PIN-0191-2017 Desarrollo de Una Aplicación Web Multiplataforma Que Facilite la Comunicación A Tiempo Real Entre Donantes de Muestras para Investigación y el Biobanco del Sistema Público Andaluz
CONSEJERÍA DE SALUD
PROYECTOS DE INNOVACIÓN EN SALUD
2017
Publicaciones científicas
- Todo
- D1
- Q1
- Q2
- Otro
Bcl-2 Inhibition to Overcome Resistance to Chemo- and Immunotherapy.
García-Aranda M, Pérez-Ruiz E, Redondo M International journal of molecular sciences 2018 Dec 8;19(12):
Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in “real world” patients
Godoy-Ortiz A, Plata Y, Alcaide J, Galeote A, Pajares B, et al. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2018 Jul;20(7):922-927
Breaking bad news to antenatal patients with strategies to lessen the pain: a qualitative study
Atienza-Carrasco J, Linares-Abad M, Padilla-Ruiz M, Morales-Gil IM Reproductive health 2018 Jan 23;15(1):11
CCR-CARESS score for predicting operative mortality in patients with colorectal cancer
Baré M, Mora L, Torà N, Gil MJ, Barrio I, et al. The British journal of surgery 2018 Dec;105(13):1853-1861
Combining statistical techniques to predict postsurgical risk of 1-year mortality for patients with colon cancer
Arostegui I, Gonzalez N, Fernández-de-Larrea N, Lázaro-Aramburu S, Baré M, et al. Clinical epidemiology 2018;10():235-251
Cost-effectiveness analysis of laparoscopic versus open surgery in colon cancer
Mar J, Anton-Ladislao A, Ibarrondo O, Arrospide A, Lázaro S, et al. Surgical endoscopy 2018 Dec;32(12):4912-4922
Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice
Blancas I, Fontanillas M, Conde V, Lao J, Martínez E, et al. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2018 Jul;20(7):862-869
Expression and Prognostic Value of Oestrogen Receptor Beta in Colorectal Cancer
Pérez-Ruiz E, Rueda A, Pérez L, Rivas-Ruiz F, Torres E, et al. Pathology oncology research : POR 2018 Oct;24(4):871-879
Factors Associated with Prolonged Patient-Attributable Delay in the Diagnosis of Colorectal Cancer
Zarcos-Pedrinaci I, Téllez T, Rivas-Ruiz F, Padilla-Ruiz MDC, Alcaide J, et al. Cancer research and treatment 2018 Oct;50(4):1270-1280
First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study
Aranda E, García-Alfonso P, Benavides M, Sánchez Ruiz A, Guillén-Ponce C, et al. European journal of cancer (Oxford, England : 1990) 2018 Sep;101():263-272
Free Thyroxine Determination in the Emergency Department Is a Predictor of Acute Pancreatitis Evolution
Callejón G, Redondo E, Garcia-Aranda M, Castilla-Alcalá JA, Prados-Torres A, et al. Pancreas 2018 Nov/Dec;47(10):1322-1327
Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes, and the subsequent clinical outcomes
Sánchez-Muñoz A, Vicioso L, Santonja A, Álvarez M, Plata-Fernández Y, et al. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2018 Feb;31(2):299-306
Outcomes of open versus laparoscopic surgery in patients with colon cancer
Quintana JM, Antón-Ladisla A, González N, Lázaro S, Baré M, et al. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2018 Sep;44(9):1344-1353
Outcomes of open versus laparoscopic surgery in patients with rectal cancer
Quintana JM, Anton-Ladislao A, Lázaro S, Gonzalez N, Bare M, et al. International journal of colorectal disease 2018 Jan;33(1):99-103
Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study)
Romero-Laorden N, Lozano R, Jayaram A, López-Campos F, Saez MI, et al. British journal of cancer 2018 Oct;119(9):1052-1059
Predictors of 1-and 2-year mortality in patients with rectal cancer
Quintana JM, González N, Lázaro S, Baré M, Fernández-de-Larrea N, et al. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland 2018 Aug;20(8):676-687
Predictors of one and two years’ mortality in patients with colon cancer: A prospective cohort study
Quintana JM, Antón-Ladislao A, González N, Lázaro S, Baré M, et al. PloS one 2018;13(6):e0199894
Regulation of Clusterin Gene Expression
Garcia-Aranda M, Serrano A, Redondo M Current protein & peptide science 2018;19(6):612-622
Slow-growing subcutaneous lesion: The value of ultrasound
García-Harana C, Fernández-Canedo MI, Romero-Madrid B, de Troya-Martín M Medicina clinica 2018 Sep 14;151(5):e29
Enlaces
Calle Severo Ochoa, 35
Parque Tecnol?gico de Andaluc?a (PTA) Campanillas,
M?laga 29590
(+34) 951 440 260
Fax: (+34) 951 440 263
